Φορτώνει......
Ibrutinib does not prevent kidney fibrosis following acute and chronic injury
Recent studies suggested that ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor, developed for the treatment of chronic lymphocytic leukemia, may prevent NLRP3 inflammasome activation in macrophages, IL-1β secretion and subsequent development of inflammation and organ fibrosis. The role of NLRP3 h...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Sci Rep |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Nature Publishing Group UK
2021
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8184891/ https://ncbi.nlm.nih.gov/pubmed/34099830 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-021-91491-x |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|